Meiser BM et al. |
Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. |
1991 |
Lancet |
pmid:1719321
|
Watanabe K et al. |
Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. |
1991 |
Transplant. Proc. |
pmid:1703706
|
Jorgensen WL |
Rusting of the lock and key model for protein-ligand binding. |
1991 |
Science |
pmid:1719636
|
Kobayashi N et al. |
Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. |
1991 |
Transplant. Proc. |
pmid:1703707
|
Moochhala SM et al. |
Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721277
|
de Paulis A et al. |
Antiinflammatory effect of FK 506 on human basophils. |
1991 |
Transplant. Proc. |
pmid:1721309
|
Su MS and Semerjian A |
Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. |
1991 |
Transplant. Proc. |
pmid:1721310
|
Reding R et al. |
Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. |
1991 |
Transplant. Proc. |
pmid:1721341
|
Uemoto S et al. |
Experience with FK 506 in living related donor liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721342
|
Hebert MF et al. |
Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721373
|
Eiras G et al. |
Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. |
1991 |
Transplant. Proc. |
pmid:1703357
|
Abu-Elmagd KM et al. |
Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. |
1991 |
Transplant. Proc. |
pmid:1721404
|
Adams CK and Famili P |
A study of the effects of the drug FK 506 on gingival tissues. |
1991 |
Transplant. Proc. |
pmid:1721405
|
Brabletz T et al. |
The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. |
1991 |
Nucleic Acids Res. |
pmid:1707162
|
Kuroki H et al. |
Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. |
1991 |
Transplant. Proc. |
pmid:1721436
|
Ito T et al. |
Bone marrow cell- and FK 506-induced donor-specific unresponsiveness in rat heart allografts. |
1991 |
Transplant. Proc. |
pmid:1721437
|
Banerji SS et al. |
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. |
1991 |
Mol. Cell. Biol. |
pmid:1712901
|
Markus PM et al. |
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. |
1991 |
Surgery |
pmid:1713358
|
Nicoletti F et al. |
FK-506 prevents diabetes in diabetes-prone BB/Wor rats. |
1991 |
Int. J. Immunopharmacol. |
pmid:1722192
|
Romanowski P et al. |
[Synthetic immunomodulators designed on the basis of natural products of microorganisms]. |
1991 |
Postepy Biochem. |
pmid:1725924
|